Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Curadev Completes First Treatment Cycle in STING Agonist Trial
Details : CRD3874-SI targets STimulator of INterferon Genes to activate immune cells for tumor eradication and is being evaluated for sarcoma.
Product Name : CRD3874-SI
Product Type : Small molecule
Upfront Cash : Not Applicable
February 27, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Sponsor : Bayer AG
Deal Size : $270.4 million
Deal Type : Collaboration
Details : The collaboration aims to discover new drug candidates for the treatment of lung diseases, cardiovascular diseases and other inflammatory diseases.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
March 23, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Sponsor : Bayer AG
Deal Size : $270.4 million
Deal Type : Collaboration